5W1G

CR1-07 unliganded Fab


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.281 
  • R-Value Work: 0.231 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses.

Clark, L.E.Mahmutovic, S.Raymond, D.D.Dilanyan, T.Koma, T.Manning, J.T.Shankar, S.Levis, S.C.Briggiler, A.M.Enria, D.A.Wucherpfennig, K.W.Paessler, S.Abraham, J.

(2018) Nat Commun 9: 1884-1884

  • DOI: 10.1038/s41467-018-04271-z
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • While five arenaviruses cause human hemorrhagic fevers in the Western Hemisphere, only Junin virus (JUNV) has a vaccine. The GP1 subunit of their envelope glycoprotein binds transferrin receptor 1 (TfR1) using a surface that substantially varies in s ...

    While five arenaviruses cause human hemorrhagic fevers in the Western Hemisphere, only Junin virus (JUNV) has a vaccine. The GP1 subunit of their envelope glycoprotein binds transferrin receptor 1 (TfR1) using a surface that substantially varies in sequence among the viruses. As such, receptor-mimicking antibodies described to date are type-specific and lack the usual breadth associated with this mode of neutralization. Here we isolate, from the blood of a recipient of the live attenuated JUNV vaccine, two antibodies that cross-neutralize Machupo virus with varying efficiency. Structures of GP1-Fab complexes explain the basis for efficient cross-neutralization, which involves avoiding receptor mimicry and targeting a conserved epitope within the receptor-binding site (RBS). The viral RBS, despite its extensive sequence diversity, is therefore a target for cross-reactive antibodies with activity against New World arenaviruses of public health concern.


    Organizational Affiliation

    Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.,Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, 77555, USA.,Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, 02115, USA. abraham@crystal.harvard.edu.,Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, 02115, USA.,Laboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. abraham@crystal.harvard.edu.,Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.,Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, 02115, USA. abraham@crystal.harvard.edu.,Program in Immunology, Harvard Medical School, Boston, MA, 02115, USA.,Instituto Nacional de Enfermedades Virales Humanas "Dr. Julio I. Maiztegui", Monteagudo 251 Pergamino, Buenos Aires, 2700, Argentina.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
CR1-07 Fab heavy chain
H
223N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
CR1-07 Fab light chain
L
222N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.281 
  • R-Value Work: 0.231 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 89.770α = 90.00
b = 137.410β = 148.66
c = 78.670γ = 90.00
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
XDSdata reduction
BALBESphasing
HKL-2000data collection
XSCALEdata scaling
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical SciencesUnited StatesAI007061
National Institutes of Health/National Institute of General Medical SciencesUnited StatesAI109740
National Institutes of Health/National Institute of General Medical SciencesUnited StatesDP5OD023084
Other privateUnited States--
Other privateUnited States--

Revision History 

  • Version 1.0: 2018-05-30
    Type: Initial release